#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

View the Show Notes Page for This Episode [https://peterattiamd.com/gayatridevi/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260713-pod-gayatridevi&utm_content=260713-pod-gayatridevi-podfeed] Become a Member to Receive Exclusive Content [https://peterattiamd.com/subscribe/?utm_source=podcast-feed&gayatridevi%20=referral&utm_campaign=260713-pod-gayatridevi&utm_content=260713-pod-gayatridevi-podfeed] Sign Up to Receive Peter's Weekly Newsletter [https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260713-pod-gayatridevi&utm_content=260713-pod-gayatridevi-podfeed] Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss: * Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45]; * How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; * The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30]; * Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; * Why forgetting names is usually normal and when word-finding problems become concerning [29:00]; * Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45]; * The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15]; * When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00]; * Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15]; * Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45]; * The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00]; * How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30]; * Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30]; * A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00]; * Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00]; * Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45]; * Risk factors for Lewy body dementia and what remains unknown [1:36:15]; * Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45]; * How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15]; * The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and * More. Connect With Peter on Twitter [https://twitter.com/PeterAttiaMD], Instagram [https://www.instagram.com/peterattiamd/], Facebook [https://www.facebook.com/peterattiamd/] and YouTube [https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg]

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

View the Show Notes Page for This Episode [https://peterattiamd.com/strengthandmuscle/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260706-pod-strengthandmuscle&utm_content=260706-pod-strengthandmuscle-podfeed] Become a Member to Receive Exclusive Content [https://peterattiamd.com/subscribe/?utm_source=podcast-feed&strengthandmuscle%20=referral&utm_campaign=260706-pod-strengthandmuscle&utm_content=260706-pod-strengthandmuscle-podfeed] Sign Up to Receive Peter's Weekly Newsletter [https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260706-pod-strengthandmuscle&utm_content=260706-pod-strengthandmuscle-podfeed] In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. We discuss: * Peter's humorous experience talking nutrition with a second grader [3:00]; * Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30]; * Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45]; * The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00]; * Grip strength as a simple yet powerful predictor of all-cause mortality [17:15]; * Is muscle strength causal or just a marker of health? [20:30]; * Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00]; * How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15]; * How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [31:00]; * The foundational principles of building muscle strength and size through resistance training [36:00]; * How to apply "progressive overload" for long-term strength and muscle gains [40:00]; * The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15]; * The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45]; * How to effectively train for power [52:30]; * Training intensity: the benefits and safety of using the "reps in reserve" method [53:30]; * How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15]; * Can bodyweight exercises build muscle as effectively as weight training? [58:15]; * How women can effectively build strength and muscle: key considerations [59:45]; * Effective methods for tracking progress in strength [1:01:45]; * Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00]; * How to balance workout frequency with recovery for optimal results [1:07:15]; * How to recognize signs of overtraining and when to consider taking rest days [1:10:45]; * Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45]; * Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00]; * How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45]; * Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15]; * The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15]; * How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00]; * How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00]; * Should beginners start with machines or free weights when resistance training? [1:37:00]; * How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; and * More. Connect With Peter on Twitter [https://twitter.com/PeterAttiaMD], Instagram [https://www.instagram.com/peterattiamd/], Facebook [https://www.facebook.com/peterattiamd/] and YouTube [https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg]

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

View the Show Notes Page for This Episode [https://peterattiamd.com/ama86/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260629-pod-ama86&utm_content=260629-pod-ama86-podfeed] Become a Member to Receive Exclusive Content [https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260629-pod-ama86&utm_content=260629-pod-ama86-podfeed] Sign Up to Receive Peter's Weekly Newsletter [https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260629-pod-ama86&utm_content=260629-pod-ama86-podfeed] In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed [https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260629-pod-ama86&utm_content=260629-pod-ama86-podfeed]or our website at the AMA #86 show notes page [http://peterattiamd.com/ama86/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260629-pod-ama86&utm_content=260629-pod-ama86-podfeed]. If you are not a subscriber, you can learn more about the subscriber benefits here [https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260629-pod-ama86&utm_content=260629-pod-ama86-podfeed]. We discuss: * The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; * Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; * How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; * Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; * Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; * The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; * Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; * Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; * The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; * Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; * Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; * Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; * Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; * Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; * Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; * Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; * Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; * The risks of using gray-market retatrutide before FDA approval [52:15]; * Key takeaways [54:30]; and * More. Connect With Peter on Twitter [https://twitter.com/PeterAttiaMD], Instagram [https://www.instagram.com/peterattiamd/], Facebook [https://www.facebook.com/peterattiamd/] and YouTube [https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg]

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

View the Show Notes Page for This Episode [https://peterattiamd.com/renatotomioka/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260622-pod-renatotomioka&utm_content=260622-pod-renatotomioka-podfeed] Become a Member to Receive Exclusive Content [https://peterattiamd.com/subscribe/?utm_source=podcast-feed&renatotomioka%20=referral&utm_campaign=260622-pod-renatotomioka&utm_content=260622-pod-renatotomioka-podfeed] Sign Up to Receive Peter's Weekly Newsletter [https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260622-pod-renatotomioka&utm_content=260622-pod-renatotomioka-podfeed] View our full terms of use [https://peterattiamd.com/terms-of-use/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260622-pod-renatotomioka&utm_content=260622-pod-renatotomioka-podfeed] Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women's health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility. Follow Dr. Tomioka's work: Instagram: @dr.renatotomioka [https://www.instagram.com/dr.renatotomioka]; Website: Renato Tomioka, M.D., Ph.D. [https://www.renatotomioka.com] We discuss: * 0:00:00 - Intro * 0:00:11 - Endometriosis: definition, prevalence, infertility risk, and theories of disease development * 0:09:03 - The biology of endometriosis: estrogen dependence, progesterone resistance, and tumor-like growth mechanisms * 0:13:25 - Adenomyosis explained: how it differs from endometriosis, why it develops, and its impact on reproductive health * 0:18:52 - Recognizing endometriosis and adenomyosis: the "6 Ds" of endometriosis and key differences in clinical presentation * 0:22:09 - Uterine fibroids: classification, symptoms, and the importance of fibroid location for bleeding and fertility * 0:24:09 - Understanding endometriosis pain: lesion-driven pain, nerve involvement, central sensitization, and the importance of early treatment * 0:28:26 - Endometriosis in young women: rising prevalence, delayed diagnosis, and barriers to care * 0:33:11 - Modern diagnosis of endometriosis: specialized ultrasound, MRI, and the decline of diagnostic laparoscopy * 0:45:52 - Clinical case example #1: Managing endometriosis in a young woman seeking pain relief while preserving future fertility * 0:54:10 - Clinical case example #2: Comparing treatment strategies for symptom control versus fertility * 1:01:24 - Endometriosis and fertility: the roles of age, embryo quality, IVF, and surgery * 1:11:50 - Clinical case example #3: Managing adenomyosis after failed IVF transfers to improve implantation and pregnancy outcomes * 1:20:51 - The funding gap in endometriosis research: disease burden, economic impact, and growing awareness * 1:22:01 - Clinical case example #4: Surgical decision-making in endometriosis—balancing pain relief, fertility preservation, and common treatment pitfalls * 1:27:43 - Common misconceptions about fertility: maternal age, embryo aneuploidy, the inefficiency of human reproduction, and the limits of IVF * 1:34:23 - Elective egg freezing: timing, success rates, the fertility funnel, and the tradeoffs of fertility preservation * 1:45:49 - Emerging fertility technologies: mitochondrial replacement, ovarian tissue preservation, stem-cell-derived eggs, and current limitations * 1:55:10 - The future of endometriosis treatment: new guidelines, biologic therapies, and unanswered questions about IVF * 1:58:30 - Why earlier diagnosis matters: reducing years of suffering from endometriosis and adenomyosis Connect With Peter on Twitter [https://twitter.com/PeterAttiaMD], Instagram [https://www.instagram.com/peterattiamd/], Facebook [https://www.facebook.com/peterattiamd/] and YouTube [https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg]

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy

View the Show Notes Page for This Episode [https://peterattiamd.com/breastcancerscreening/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260601-pod-breastcancerscreening&utm_content=260601-pod-breastcancerscreening-podfeed] Become a Member to Receive Exclusive Content [https://peterattiamd.com/subscribe/?utm_source=podcast-feed&breastcancerscreening=referral&utm_campaign=260601-pod-breastcancerscreening&utm_content=260601-pod-sleeppharmacology-podfeed] Sign Up to Receive Peter's Weekly Newsletter [https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260601-pod-breastcancerscreening&utm_content=260601-pod-breastcancerscreening-podfeed] In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual's risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment. We discuss: * Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45]; * Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30]; * A framework for personalizing screening [8:45]; * Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30]; * Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45]; * Mammography as the foundation of breast cancer screening: detecting ductal carcinoma in situ (DCIS) and the advantages of 3D versus 2D mammography [21:00]; * MRI for high-risk women: the benefits of supplemental screening, abbreviated MRI, and the emerging role of contrast-enhanced mammography [23:00]; * The role of ultrasound: supplemental cancer detection, diagnostic evaluation, and limitations compared with mammography and MRI [26:00]; * Choosing the right breast cancer screening strategy: imaging modality selection, screening hierarchies, and the importance of imaging center quality [28:00]; * How often should you screen for breast cancer? [30:15]; * At what age should you start screening? [37:30]; * Breast cancer in younger women: aggressive tumor biology, BRCA-related risk, breast density, and individualized decisions about when to begin screening [41:45]; * Inflammatory breast cancer, the limitations of screening mammography for symptomatic disease, and the importance of promptly evaluating new breast symptoms in both women and men [44:45]; * From risk assessment to personalized screening: a practical framework for reducing breast cancer mortality through earlier and more effective detection [46:30]; and * More. Connect With Peter on Twitter [https://twitter.com/PeterAttiaMD], Instagram [https://www.instagram.com/peterattiamd/], Facebook [https://www.facebook.com/peterattiamd/] and YouTube [https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg]